Literature DB >> 1690527

Antimyelin basic protein and antimyelin antibody-producing cells in multiple sclerosis.

T Olsson1, S Baig, B Höjeberg, H Link.   

Abstract

The B-cell response to myelin and myelin basic protein was studied in patients with multiple sclerosis and in patients with acute aseptic meningoencephalitis by using a nitrocellulose immunospot assay. This method allows detection of single cells producing antibodies. Twenty-seven (79%) of 34 patients with multiple sclerosis had cells producing IgG antibodies against myelin, and 11 (57%) of 19 had cells producing IgG antibodies against myelin basic protein in cerebrospinal fluid (CSF), with mean values of 30 and 14 per 10(4) mononuclear cells, respectively. Total numbers of IgG-producing cells occurred at a mean number of 75 per 10(4) CSF cells. Cells producing antimyelin or anti-myelin basic protein antibodies of IgA or IgM isotypes were rarely found in CSF. Patients with acute aseptic meningoencephalitis less frequently showed CSF cells producing IgG antibodies against myelin and myelin basic protein. No cells producing antibodies against myelin or myelin basic protein were detected in peripheral blood of patients with multiple sclerosis or meningoencephalitis. Thus, a majority of patients with multiple sclerosis had CSF cells that produced IgG antibodies against myelin and myelin basic protein. These cells comprised a large proportion of the total IgG-producing cells. A pronounced B-cell response against autoantigens produced at the target for immune attack might be important in the pathogenesis of multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1690527     DOI: 10.1002/ana.410270207

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  22 in total

1.  Antigen microarrays identify CNS-produced autoantibodies in RRMS.

Authors:  F J Quintana; M F Farez; G Izquierdo; M Lucas; I R Cohen; H L Weiner
Journal:  Neurology       Date:  2012-01-18       Impact factor: 9.910

2.  Autoimmune disease and the nervous system.

Authors:  L Steinman
Journal:  West J Med       Date:  1992-06

Review 3.  Intravenous immunoglobulin and multiple sclerosis.

Authors:  Anat Achiron; Shmuel Miron
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

4.  Ro/SS-A- and La/SS-B-reactive B lymphocytes in peripheral blood of patients with Sjögren's syndrome.

Authors:  A Halse; M Wahren-Herlenius; R Jonsson
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

5.  Ro/SS-A-reactive B lymphocytes in salivary glands and peripheral blood of patients with Sjögren's syndrome.

Authors:  A Halse; J B Harley; U Kroneld; R Jonsson
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

6.  Susceptibility to multiple sclerosis is associated with the proximal immunoglobulin heavy chain variable region.

Authors:  M A Walter; W T Gibson; G C Ebers; D W Cox
Journal:  J Clin Invest       Date:  1991-04       Impact factor: 14.808

7.  Susceptibility to multiple sclerosis and the immunoglobulin heavy chain variable region.

Authors:  N W Wood; S J Sawcer; H F Kellar-Wood; P Holmans; D Clayton; N Robertson; D A Compston
Journal:  J Neurol       Date:  1995-10       Impact factor: 4.849

8.  Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis.

Authors:  Y Qin; P Duquette; Y Zhang; P Talbot; R Poole; J Antel
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

9.  Intrathecal immune response in patients with neuroborreliosis: specificity of antibodies for neuronal proteins.

Authors:  R Kaiser
Journal:  J Neurol       Date:  1995-05       Impact factor: 4.849

10.  Myelin basic protein-specific T lymphocyte repertoire in multiple sclerosis. Complexity of the response and dominance of nested epitopes due to recruitment of multiple T cell clones.

Authors:  E Meinl; F Weber; K Drexler; C Morelle; M Ott; G Saruhan-Direskeneli; N Goebels; B Ertl; G Jechart; G Giegerich
Journal:  J Clin Invest       Date:  1993-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.